title: Continued treatment of chronic hepatitis C despite development of interferon-associated retinopathy.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Cedar
authors.forename: Krysia L
authors.initials: KL
authors.lastname: Zancosky
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Oliva
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Molloy
authors.forename: David J
authors.initials: DJ
authors.lastname: Weissgold
authors.forename: Edward L
authors.initials: EL
authors.lastname: Krawitt
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012164:Retinal Diseases / Q000139:chemically induced*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins